HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Karsten Wiebe Thorsten Wahlers Axel Haverich Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Franke, U. Articles by Haverich, A. Search for Related Content PubMed PubMed Citation Articles by Franke, U. Articles by Haverich, A.

Eur J Cardiothorac Surg 2000;18:447-452
© 2000 Elsevier Science NL

Ten years experience with lung and heart–lung transplantation in primary and secondary pulmonary hypertension

^a Department of Thoracic and Cardiovascular Surgery, Friedrich-Schiller-University, D-07740 Jena, Germany
^b Department of Thoracic and Cardiovascular Surgery, Medical School, Hannover, Germany

Received 28 December 1999; received in revised form 19 June 2000; accepted 28 June 2000.

Corresponding author. Tel.: +49-3641-934-801; fax: +49-3641-934-802
e-mail: ulrich.franke{at}med.uni-jena.de

Objective: Patients with primary pulmonary hypertension (PPHT) have a worse natural outcome compared with those with secondary pulmonary hypertension in Eisenmenger's syndrome (ES) and chronic pulmonary embolism (CPE). Lung transplantation (SLTx, DLTx, HLTx) still remains the only therapeutical option for patients with this type of endstage lung disease. Methods: From 1988 to 1998, 63 patients underwent lung transplantation for PPHT (n=29, 9 m, 20 f, 2 SLTx, 14 DLTx, 13 HLTx), ES (n=29, 13 m, 16 f, 2 SLTx, 3 DLTx, 24 HLTx) or CPE (n=5, 2 m, 3 f, 1 SLTx, 2 DLTx, 2 HLTx). Groups were comparable for NYHA functional class, preoperative pulmonary arterial pressure, recipient and donor age, ischemic time, necessity and duration of cardiopulmonary bypass and cross-match. Results: The 1-, 3- and 5-year survival was 52, 40 and 35% for the PPHT-group, 83, 78 and 74% for the ES-group and 80, 60 and 60% for the CPE-group, respectively (P=0.026, P=0.033, P=0.082 for 1-, 3- and 5-year survival). Patients following DLTx showed a lower 1-year survival rate as compared with patients after HLTx both in PPHT patients (36 vs. 62%, P=0.091) and in ES patients (67 vs. 83%, P=0.213). The incidence of bronchiolitis obliterans syndrome was 29% at 1 year and 45% at 3 years for the PPHT-group vs. 17 and 65% for the ES-group (n.s. in between groups). Excluding postoperative ventilation time (PPHT-group: 26.8±24.0 days vs. ES-group: 16.1±30.8 days, P=0.011) and a higher incidence of infectious causes of death (PPHT-group n=8 vs. ES-group n=1, P=0.017) groups were comparable with regard to their postoperative courses. Conclusions: It is concluded, that predominantly the underlying primary disease influences graft survival after lung transplantation in patients with pulmonary hypertension compared with all other patient and procedure dependent factors. Lung transplantation in patients with PPHT requires further investigations to achieve results comparable with other indications.

Key Words: Primary pulmonary hypertension • Eisenmenger's syndrome • Chronic pulmonary embolism • Lung transplantation • Heart–lung transplantation • Bronchiolitis obliterans syndrome

This article has been cited by other articles:

				G. Yung Lung Transplantation and Pulmonary Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 149 - 156. [Abstract] [PDF]

				M.-T. Kasimir, G. Seebacher, P. Jaksch, G. Winkler, K. Schmid, G. M. Marta, P. Simon, and W. Klepetko Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 776 - 781. [Abstract] [Full Text] [PDF]

				R. L. Doyle, D. McCrory, R. N. Channick, G. Simonneau, and J. Conte Surgical Treatments/Interventions for Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 63S - 71S. [Abstract] [Full Text] [PDF]

				W. Klepetko, E. Mayer, J. Sandoval, E. P. Trulock, J.-L. Vachiery, P. Dartevelle, J. Pepke-Zaba, S. W. Jamieson, I. Lang, and P. Corris Interventional and surgical modalities of treatment for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 73S - 80S. [Abstract] [Full Text] [PDF]